Preparation of polypeptide hydrogel and application of polypeptide hydrogel in myocardial ischemia-reperfusion injury
By developing the ROS-responsive peptide hydrogel Apelin-13@Gel TK, ROS cuts the thioketone bond in the polypeptide gel-forming factor to achieve slow release of Apelin-13, solving myocardial ischemia and reperfusion injury after acute myocardial infarction The treatment difficulties significantly improve cardiac function recovery and biocompatibility.
Patent Information
- Application Number
- CN202411126673.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
AI Technical Summary
The complex mechanism of myocardial ischemia-reperfusion injury after acute myocardial infarction is not fully understood, and there is a lack of effective clinical treatment options, which affects the prognosis of patients.
A peptide hydrogel Apelin-13@Gel TK was developed to form a supramolecular hydrogel formed by non-covalent interactions. The thioketone bond in the polypeptide gel forming factor was cleaved using ROS-responsive thioketone bond to achieve Apelin-13 slow release to alleviate myocardial ischemia and reperfusion injury.
In myocardial ischemia and reperfusion injury, high-level ROS triggers hydrogel disintegration and rapid release of Apelin-13, reducing cardiomyocyte apoptosis; in a low-ROS environment, continuous release of Apelin-13 promotes angiogenesis and improves cardiac function recovery. , showing good biocompatibility and biodegradability, suitable for clinical applications.
Smart Images

Figure CN119019856A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology and new medical technology, and relates to the preparation of a polypeptide hydrogel and its application in myocardial ischemia-reperfusion injury; specifically, it relates to a preparation method of a ROS-responsive polypeptide hydrogel and its application in myocardial ischemia-reperfusion injury. Background Art
[0002] Acute myocardial infarction (AMI) is mainly caused by sudden obstruction of the coronary artery, leading to acute and persistent ischemic necrosis of myocardial tissue. It is one of the leading causes of death and disability worldwide. In recent years, with the widespread use of thrombolysis and percutaneous coronary intervention (PCI), the mortality rate of AMI patients has gradually decreased. However, restoration of blood flow after early reperfusion will aggravate the tissue damage caused by the initial ischemia, which is called myocardial ischemia-reperfusion (MI / R) injury. This pathological injury is mainly caused by the interaction of excessive reactive oxygen species (ROS), intracellular calcium ion overload and inflammatory response. High levels of ROS can also affect the mitochondrial permeability transition pore, leading to more severe cardiac tissue damage. Currently, in clinical practice, there is limited understanding of the complex mechanisms of MI / R injury and a lack of effective clinical treatment options. Solving this problem is crucial to further improve the prognosis of patients with MI / R injury. Summary of the invention
[0003] In view of the above problems, the present invention aims to propose a preparation method of polypeptide hydrogel and its application in myocardial ischemia-reperfusion injury.
[0004] The technical scheme of the present invention is: a method for preparing a polypeptide hydrogel according to the present invention, comprising polypeptide gelling factor YFF-TK-FFY and adipose cell factor Apelin-13;
[0005] The polypeptide gelling factor YFF-TK-FFY and the adipocyte factor Apelin-13 are co-assembled through non-covalent interactions to form a supramolecular polypeptide hydrogel Apelin-13@Gel TK.
[0006] Further, the preparation steps are as follows:
[0007] Step (1): synthesizing the peptide gelling factor YFF-TK-FFY containing impurities by solid phase peptide synthesis;
[0008] Step (2): purifying the polypeptide gelling factor containing impurities in the previous step by semi-preparative high performance liquid chromatography and freeze-drying, thereby obtaining a white powdery, pure polypeptide gelling factor YFF-TK-FFY;
[0009] Step (3): The prepared polypeptide gelling factor YFF-TK-FFY and the prepared adipocyte factor Apelin-13 are mixed in proportion in phosphate buffered saline, heated and then cooled to finally form a supramolecular polypeptide hydrogel Apelin-13@GelTK.
[0010] Further, in step (1), the specific synthesis process is as follows:
[0011] First, 2-chlorotrityl chloride resin (2 g) was swollen in 20 mL of N,N-dimethylformamide (DMF) for 20 min;
[0012] Secondly, the first amino acid Fmoc-Tyr(OtBu)-OH (3 mmol) was grafted onto the resin in a DMF solution with N,N-diisopropylethylamine (DIPEA, 1.5 mL) for 1 hour; after washing three times with DMF to remove the ungrafted amino acid in the reaction solution, the resin was capped with a capping solution (DMF: methanol = 19:1) for 30 minutes;
[0013] Then, the Fmoc protecting group was removed with 20% piperidine–DMF solution for 30 min, and then washed three times with DMF to remove the residual piperidine in the reaction solution;
[0014] Next, the next Fmoc-protected amino acid Fmoc-Phe-OH (3 mmol) was coupled to the free amino group using HOBt / HBTU / DIPEA as a coupling reagent; Fmoc-Phe-OH was coupled again by repeating these coupling and deprotection steps, and finally 1 mmol of TK-COOH was added so that the carboxyl groups at both ends could react and connect with the free amino group;
[0015] Finally, after washing with DMF solution, isopropanol and n-hexane for 5 times respectively, the synthesized polypeptide was cut from the resin with 95% trifluoroacetic acid (TFA)-dichloromethane solution for 30 minutes twice; since it is difficult to completely remove the unreacted compounds in each washing, what is cut off is the polypeptide gelling factor containing impurities. Since the cut polypeptide gelling factor contains some impurities, it still needs further purification.
[0016] Furthermore, in step (2), the specific synthesis process is as follows: using water-acetonitrile added with 0.1% TFA as a mobile phase eluent to purify a polypeptide solution containing impurities; after obtaining the purified polypeptide solution, using a rotary evaporator to remove the acetonitrile in the purified polypeptide solution, and drying it under a freeze dryer for 24 hours to remove the water in the purified polypeptide solution, finally obtaining a pure polypeptide gelling factor YFF-TK-FFY in the form of a white powder.
[0017] Furthermore, the obtained polypeptide gelling factor YFF-TK-FFY has the following sequence: tyrosine-phenylalanine-phenylalanine-thioketal-phenylalanine-phenylalanine-tyrosine.
[0018] Furthermore, in step (3), the specific synthesis process is as follows: the polypeptide gelling factor YFF-TK-FFY and Apelin-13 are mixed in a molar ratio of 1:100 in phosphate buffered saline (PBS) with a pH value of 7.4, and then the solution is heated to 60°C and cooled to room temperature (about 25°C). During the heating and cooling process, the adipocyte factor Apelin-13 can co-assemble with the polypeptide gelling factor through non-covalent interactions, forming a dense nanofiber network structure at the microscopic level, and finally forming the polypeptide hydrogel Apelin-13@Gel TK at the macroscopic level.
[0019] Furthermore, the polypeptide hydrogel Apelin-13@Gel TK can specifically target high levels of ROS in myocardial ischemia-reperfusion injury and undergo depolymerization; the specific mechanism is that ROS can specifically cleave the thioketone bonds in the gelling factor and cleave them to enhance its water solubility, thereby leading to the depolymerization of the supramolecular hydrogel and ultimately achieving the slow release of Apelin-13, thereby achieving the treatment of myocardial ischemia-reperfusion injury.
[0020] Furthermore, the polypeptide hydrogel Apelin-13@Gel TK responds to high levels of ROS in vivo or in vitro, and the thioketal bonds break and convert into YFF-SH, thereby triggering the disintegration of the hydrogel, causing the hydrogel to transform from a gel state to a liquid state and responsively release Apelin-13.
[0021] Furthermore, the polypeptide hydrogel Apelin-13@Gel TK is used for local administration after myocardial ischemia-reperfusion injury to reduce the local ROS level and improve the bioavailability of Apelin-13.
[0022] The principle of the present invention is: Apelin, as an endogenous ligand of G protein-coupled receptor APJ, plays an important role in heart development and various cardiovascular diseases; the apelin precursor composed of 77 amino acids can be cut into active apelin peptides of different lengths, among which Apelin-13 and its modified form Pyr-Apelin-13 are the most active subtypes; studies have shown that Apelin has multiple protective effects in different pathological stages of myocardial infarction and ischemia-reperfusion injury; in the early stage of MI / R injury, Apelin reduces cardiomyocyte apoptosis by reducing TUNEL-positive cells and reducing caspase-3 activity in myocardial tissue; in the later repair stage, Apelin can promote angiogenesis and contribute to tissue repair, ultimately improving cardiac function; these findings indicate that Apelin may be an effective choice for the treatment of myocardial infarction and MI / R injury; however, the half-life of Apelin in human plasma is extremely short, less than 10 minutes, which greatly limits its clinical application; therefore, effective delivery of apelin peptides is a key issue in the treatment of MI / R injury.
[0023] Hydrogels are a class of biomaterials widely used in biomedical research; among them, supramolecular peptide hydrogels have attracted much attention due to their simple synthesis, controllable structure, easy functionalization and excellent biocompatibility; with these superior properties, peptide-based hydrogels can be used as injectable drug carriers to encapsulate bioactive substances for the treatment of various diseases; supramolecular peptide hydrogels are used to treat diseases such as ovarian tumors and premature ovarian failure; it is worth noting that the sustained release of V1-Cal was previously achieved in the NapFFY structure, which reduced myocardial damage and improved cardiac function, demonstrating its potential application in myocardial infarction.
[0024] In view of the fact that high levels of ROS in the ischemia-reperfusion myocardial tissue microenvironment are a promising therapeutic target, the present invention has developed an intelligent ROS-responsive peptide hydrogel system for efficiently and stably loading Apelin-13 and intelligently releasing it in response to ROS; the hydrogel Tyr-Phe-Phe-TK-Phe-Phe-Tyr (YFF-TK-FFY) has a commonly used self-assembly motif Phe-Phe-Tyr and a ROS-responsive thiol-disulfide bond (TK), which responds to increased ROS levels; the supramolecular hydrogel Gel YFF-TK-FFY (Gel TK) is simply synthesized and obtained through a heating and cooling process; Apelin-13 containing aromatic groups is co-assembled with YFF-TK-FFY to form Apelin-13@Gel TK complex; hypothesized that, through ROS-mediated cleavage of the thioketal bond, YFF-TK-FFY will transform into a YFF-SH structure, initiating the disintegration of the hydrogel and releasing Apelin-13; in the core area of MI / R injury with higher ROS levels, the rapidly released Apelin-13 can alleviate cardiomyocyte apoptosis; while in the edge area with lower ROS levels, the continuous release of unresponsive Apelin-13 promotes angiogenesis and lymphatic remodeling in the subsequent repair stage; these mechanisms together help to alleviate cardiac fibrosis and enhance cardiac function recovery.
[0025] The beneficial effects of the present invention are: the present invention triggers the disintegration of the hydrogel and the responsive release of Apelin-13 through high-level ROS, and quickly responds to the release of ROS and alleviates myocardial ischemia-reperfusion injury in the core area of myocardial ischemia-reperfusion injury under the high-level ROS environment, and can continuously and slowly release Apelin-13 and promote angiogenesis in the marginal area under the action of low-level ROS in the marginal area; in vivo studies show enhanced therapeutic effects; in addition, this hydrogel has good biocompatibility and biodegradability, and is suitable for clinical applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 It is a schematic diagram of the effect of the polypeptide hydrogel in the present invention;
[0027] Figure 2 It is the synthesis route of the polypeptide gelling factor YFF-TK-FFY in the present invention;
[0028] Figure 3 It is a frequency (strain: 1.0%) correlation comparison diagram of the dynamic storage modulus (G') and loss modulus (G") of Gel TK in the embodiment of the present invention;
[0029] Figure 4It is a frequency (strain: 1.0%) correlation comparison diagram of the dynamic storage modulus (G') and loss modulus (G") of Apelin-13@Gel TK in the embodiment of the present invention;
[0030] Figure 5 is a statistical diagram of cell activity after co-incubation of myocardial H9C2 cells with hydrogel in an embodiment of the present invention;
[0031] Figure 6 is a statistical graph of cell activity of H9C2 cells after co-incubation with different groups under hypoxia-reoxygenation conditions in an embodiment of the present invention;
[0032] Figure 7 is a graph showing the proportion of apoptotic myocardial cells in the infarction site of C57BL / 6 mice subjected to local myocardial ischemia-reperfusion injury 3 days after administration of the drug;
[0033] Figure 8 This is a schematic diagram of angiogenesis in the injured edge area of C57BL / 6 mice subjected to local myocardial ischemia-reperfusion injury 2 weeks after administration of the drug in the embodiment of the present invention;
[0034] Fig. 9 It is a comparative schematic diagram of the test levels of liver and kidney function indicators of each group of mice killed at the end of the experiment in the embodiment of the present invention;
[0035] Fig.10 These are representative H&E staining images of the main organs of mice in each group killed at the end of the experiment in the examples of the present invention. DETAILED DESCRIPTION
[0036] The specific technical scheme of the present invention is further described in detail below with reference to specific examples.
[0037] Example 1: Synthesis and purification of polypeptide gelation factor YFF-TK-FFY
[0038] 1. Materials and equipment:
[0039] Required reagents: Fmoc-protected amino acids, 2-chlorotrityl chloride resin, TK-COOH, HBTU, HOBt, N,N-dimethylformamide, dichloromethane, trifluoroacetic acid, isopropanol, n-hexane, etc.;
[0040] Equipment: solid phase peptide synthesizer, high performance liquid chromatography (HPLC), mass spectrometer (MS), refrigerated centrifuge, ultrapure water system, nuclear magnetic resonance instrument, etc.
[0041] 2. Steps:
[0042] Solid phase peptide synthesis: A peptide gelling factor with the sequence of tyrosine-phenylalanine-phenylalanine-thioketal-phenylalanine-phenylalanine-tyrosine) was synthesized using a solid phase peptide synthesizer; first, 2-chlorotrityl chloride resin (2 g) was swollen in 20 mL of N,N-dimethylformamide (DMF) for 20 minutes;
[0043] Then the first amino acid Fmoc-Tyr(OtBu)-OH (3 mmol) was grafted onto the resin in a DMF solution with N,N-diisopropylethylamine (DIPEA, 1.5 mL) for 1 hour; after washing three times with DMF to remove the ungrafted amino acid in the reaction solution, the resin was capped with a capping solution (DMF: methanol = 19:1) for 30 minutes;
[0044] Next, the Fmoc protecting group was removed with a 20% piperidine-DMF solution for 30 min, and then the reaction solution was washed three times with DMF to remove the residual piperidine. Then, the next Fmoc-protected amino acid Fmoc-Phe-OH (3 mmol) was coupled to the free amino group using HOBt / HBTU / DIPEA as a coupling reagent. The next Fmoc-Phe-OH connection was achieved by repeating these coupling and deprotection steps, and finally 1 mmol of TK-COOH was added to react its two ends with the exposed amino groups in the liquid-phase synthesis system.
[0045] Finally, after washing with DMF solution, isopropanol and n-hexane for 5 times, the synthesized peptide was cleaved from the resin with 95% trifluoroacetic acid-dichloromethane solution for 30 minutes twice; since it is difficult to completely remove the unreacted compounds each time, the cleaved peptide solution contains some impurities and still needs further purification (such as Figure 2 shown);
[0046] Purification: Purify the polypeptide gelling factor containing impurities in the previous step by semi-preparative high performance liquid chromatography; use water-acetonitrile supplemented with 0.1% TFA as the mobile phase eluent (from 60:40 to 0:100) to purify the polypeptide gelling factor containing impurities;
[0047] After obtaining the purified polypeptide gelling factor, the acetonitrile in the purified polypeptide gelling factor was removed by using a rotary evaporator, and the solution was dried in a freeze dryer for 24 hours to remove the water in the purified polypeptide solution, and finally a pure polypeptide gelling factor YFF-TK-FFY in the form of white powder was obtained.
[0048] Structural confirmation: The correctness of the synthesis of YFF-TK-FFY was confirmed by mass spectrometry, and the molecular structure of YFF-TK-FFY was determined by nuclear magnetic resonance spectrum. Specifically, the predicted molecular weight of YFF-TK-FFY after hydrogenation was 1167.4m / z, which was consistent with the observed result of 1167.3m / z, proving the correctness of the synthesis; secondly, the specific observation results of its hydrogen spectrum and carbon spectrum were as follows: 1 H NMRspectrum(500MHz,DMSO-d6)δ(ppm):8.17(d,J=7.7Hz,2H),8.02(d,J=8.4Hz,4H),7.22(d,J=3 .5Hz,8H),7.19(s,8H),7.17–7.11(m,4H),7.02(d,J=8.1Hz,4H),6.67(d,J=8.2Hz,4H),4.55(td, J=8.7,4.6Hz,2H),4.48(dt,J=9.1,4.7Hz,2H),4.39(td,J=7.7,5.5Hz,2H),3.04–2.92(m,6H),2. 85–2.76(m,4H),2.66(dd,J=13.9,9.9Hz,2H),2.57–2.52(m,4H),2.32–2.18(m,4H),1.45(s,6H). 13 C NMR spectrum (126MHz, DMSO)δ:172.59,170.77,170.69,170.02,155.81,137.69,137.42,129.90,129.10,129.03,127.83,127.75,127.15,126.08,125.95,114.87,55.28,53.65,53.49,53.44,37.37,37.24,35.87,35.08,30.40,25.31, which is consistent with the predicted results, proving the purity of the synthesized YFF-TK-FFY and the correctness of the molecular structure.
[0049] Example 2: Measurement of critical aggregation concentration (CAC) of polypeptide gelling factor YFF-TK-FFY
[0050] 1. Materials and equipment:
[0051] Required reagents: polypeptide gelation factor YFF-TK-FFY, PBS buffer (pH 7.4);
[0052] Equipment: UV-visible spectrophotometer;
[0053] 2. Steps:
[0054] Measurement of critical aggregation concentration (CAC): YFF-TK-FFY solutions with concentrations ranging from 2.5 mM to 2 μM were prepared in PBS (10 mM, pH 7.4); the transmittance of different solutions at wavelengths of 300 nm to 700 nm was then detected using a UV-visible spectrophotometer; the transmittance at 400 nm was used to calculate the CAC of YFF-TK-FFY.
[0055] Example 3: Co-assembly of adipocyte factor Apelin-13 and polypeptide gelation factor YFF-TK-FFY
[0056] 1. Materials and equipment:
[0057] Required reagents: polypeptide gel factor YFF-TK-FFY, adipocyte factor Apelin-13, PBS buffer (pH 7.4), etc.
[0058] Equipment: Metal bath heater;
[0059] 2. Steps:
[0060] Preparation of hydrogel: Dissolve the polypeptide gelling factor YFF-TK-FFY in PBS buffer at a concentration of 1.0wt%; heat to 60°C and add the adipocyte factor Apelin-13 at a molar ratio of 1:100, then cool to room temperature. The formation of a transparent and stable supramolecular polypeptide hydrogel Apelin-13@Gel TK can be observed with the naked eye.
[0061] Example 4: Observation of the micro-nanostructure of Apelin-13@Gel TK
[0062] 1. Materials and equipment:
[0063] Required reagents: Apelin-13, YFF-TK-FYY, PBS, etc.;
[0064] Equipment: Transmission electron microscope (TEM);
[0065] 2. Steps:
[0066] TEM sample preparation: Apelin-13@Gel TK was diluted 50 times and dropped onto a carbon-coated copper grid and air-dried overnight; then a JEM-2100 transmission electron microscope (JEOL, Japan) was used to observe and obtain TEM images.
[0067] Example 5: Secondary structure measurement of Apelin-13@Gel TK
[0068] 1. Materials and equipment:
[0069] Required reagents: adipose cell factor Apelin-13, polypeptide gelation factor YFF-TK-FYY, Na2CO3-NaH2PO4 buffer (pH=7.4), etc.;
[0070] Equipment: Circular dichroism (CD) spectrometer;
[0071] 2. Steps:
[0072] CD measurement: First, 1 wt% polypeptide hydrogel Apelin-13@Gel TK was prepared using Na2CO3-NaH2PO4 buffer (pH = 7.4), and then it was diluted 20 times with the buffer. Without thermocouple temperature control, data were recorded in the wavelength range of 180-400 nm with a bandwidth of 0.1 nm.
[0073] Example 6: Measurement of rheological properties of Apelin-13@Gel TK
[0074] 1. Materials and equipment:
[0075] Required reagents: Apelin-13, peptide gelation factor YFF-TK-FYY, PBS, etc.;
[0076] Equipment: Rheometer;
[0077] 2. Steps:
[0078] Rheological test: The rheological test was performed by Haake RheoStress 6000 instrument (Thermo Scientific); briefly, 1.0 wt% Apelin-13@Gel TK was first prepared and then evenly spread on the rheometer test bench for rheological test (eg Figure 3 , Figure 4 shown).
[0079] Example 7: ROS-triggered hydrogel dissolution
[0080] 1. Materials and equipment:
[0081] Required reagents: Apelin-13@Gel TK, H2O2, PBS;
[0082] Equipment: High performance liquid chromatography (HPLC), cell culture incubator, TEM, etc.
[0083] 2. Steps:
[0084] Apelin-13@Gel TK dissolution: Apelin-13@Gel TK was incubated with 50uL 100mM H2O2 at room temperature overnight; the dissolution of the hydrogel could be observed macroscopically; then, the changes in the nanostructure of Apelin-13@Gel TK were observed by TEM; finally, HPLC was used to analyze the product YFF-SH after the polypeptide gelling factor YFF-TK-FFY in Gel TK was cleaved by ROS.
[0085] Example 8: Measurement of drug release rate of YFF-TK-FFY under the action of ROS
[0086] 1. Materials and equipment:
[0087] Required reagents: Gel TK, H2O2, PBS, apelin-13, 5(6)-FAM SE, DIPEA, DMF;
[0088] Equipment: High performance liquid chromatography, etc.
[0089] 2. Steps:
[0090] a) Drug labeling: First, 10 μmol of apelin-13 was added to 1 mL of DMF, and 10 μmol of 5(6)-FAM SE and 20 μmol of DIPEA were added to label Apelin-13 with FITC fluorescent group; then, FITC-Apelin-13 labeled with fluorescent group was purified by HPLC and freeze-dried;
[0091] b) Drug release: 200 μL of FITC-Apelin-13@Gel TK was incubated with 1 mL of H2O2 (1 mM), samples were taken at different time points, and the release amount of Apelin-13 was quantitatively analyzed by fluorescence spectrophotometer.
[0092] Example 9: CCK-8 detection of H9c2 cell activity
[0093] 1. Materials and equipment:
[0094] Required biological materials: H9c2 cells, 96-well cell culture plates;
[0095] Required reagents: CCK-8, DMEM medium, fetal bovine serum (FBS), Gel TK, PBS;
[0096] Equipment: cell culture incubator, microplate reader;
[0097] 2. Steps:
[0098] Cell culture: H9c2 cells were cultured in DMEM medium containing 10% FBS;
[0099] Cell viability assay: H9c2 cells were seeded in 96-well plates (5000 cells / well); 20 μL of complete medium and 1.0 wt% Gel TK were added to each well; after 24 hours, cell proliferation was detected using the CCK-8 assay according to the protocol provided by the kit; in brief, the medium in each well was replaced with 100 μL DMEM containing 10 μL CCK-8; after incubation at 37°C for 1 hour, the optical density (OD) value of the absorbance at 450 nm was measured in a microplate reader (SpectraMax iD3, Molecular Devices); each experiment was performed at least three times (eg, Figure 6 shown).
[0100] Example 10: Evaluation of the effect of Apelin-13@Gel TK intervention on H9c2 cells after hypoxia-reoxygenation
[0101] 1. Materials and equipment:
[0102] Required reagents: CCK-8, DMEM medium, fetal bovine serum (FBS), Apelin-13, Gel TK, PBS;
[0103] Equipment: cell culture incubator, microplate reader.
[0104] 2. Steps:
[0105] a) Drug assembly: Apelin-13 and YFF-TK-FFY in different ratios were co-assembled by heating and cooling, and the concentration ratio was gradually doubled from 1:800 to 1:25;
[0106] b) Cell viability assay:
[0107] CCK-8 kit was used to visually determine cell viability; H9c2 cells were seeded in 96-well plates (5000 cells / well); cells in the control group were always in normoxia, while cells in the experimental group were restored to normoxia (21% O2) for 24 h after hypoxia (1% O2) for 6 h, and given different interventions: hydrogel alone or hydrogel encapsulated with different concentrations of Apelin-13 / YFF-TK-FFY (ratios of 1:800, 1:400, 1:200, 1:100, 1:50 and 1:25), and cell proliferation was detected using CCK-8 assay according to the protocol provided by the kit after 24 h; Briefly, the culture medium in each well was replaced with 100 μL DMEM containing 10 μL CCK-8; After incubation at 37°C for 1 h, the optical density (OD) value of absorbance at 450 nm was measured in a microplate reader; Each experiment was performed at least three times (e.g. Figure 6 shown).
[0108] Example 11: Establishment of animal model and therapeutic intervention
[0109] 1. Materials and equipment:
[0110] Required biological materials: C57BL / 6 mice
[0111] Required reagents: PBS (pH 7.4), Gel TK, apelin-13, Apelin-13@Gel TK, etc.;
[0112] Equipment: ALC-V8S small animal ventilator (ALCBIO, China), micro-syringe, etc.;
[0113] 2. Steps:
[0114] Animal model establishment: According to the experimental protocol, a myocardial ischemia-reperfusion (MI / R) injury model was established in mice; mice were anesthetized and ventilated using an ALC-V8S small animal ventilator (ALCBIO, China); the chest was opened, the pectoralis major and pectoralis minor muscles were separated, and the heart was exposed through the fourth intercostal incision; the left anterior descending artery (LAD) was ligated with 6-0 silk suture, and myocardial infarction (MI) was confirmed by typical ST-segment elevation on the electrocardiogram (ECG); 45 minutes later, the ligation was released to restore LAD blood flow, and ST-segment depression was observed on the ECG; five minutes before the ligation was released, 20 μL of different interventions (PBS, Gel TK, Apelin-13, Apelin-13@Gel TK) were injected into the core and edge areas of the infarct injury 5 times by a microsyringe (Hamilton); the control group received the same surgery without ligating the left anterior descending artery, and then followed the experimental protocol.
[0115] Example 12: Evaluation of the therapeutic effect of Apelin-13@Gel TK in the infarct core area in vivo
[0116] 1. Materials and equipment:
[0117] Required biological materials: C57BL / 6 mice in each group after modeling and intervention
[0118] Required reagents: 4% paraformaldehyde, TUNEL staining kit, anti-cTnT antibody, fluorescent secondary antibody, DAPI staining solution, PBS, etc.;
[0119] Required equipment: tissue slicer, transmission electron microscope, confocal microscope, etc.;
[0120] 2. Steps:
[0121] Tissue staining: On the third day after modeling and treatment intervention, the mice were anesthetized and the heart tissues were removed, embedded in paraffin and sliced; the heart tissue sections were analyzed using terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL); the specific steps were to remove the heart tissues of mice with myocardial ischemia-reperfusion injury after different treatments, and then fix them with 4% paraformaldehyde solution; and the tissue sections were embedded in paraffin and sliced, incubated in xylene (10 minutes) for 3 times, and then dehydrated with ethanol gradient; finally, the samples were washed with distilled water; the obvious liquid in the target tissue sections was eliminated; the protease working solution was added to cover the samples, and then incubated at 37°C for 25 minutes; then, the samples were washed with PBS for 3 times and the permeation working solution (0.1% Triton X-100) to cover the tissue sections, and then incubate at room temperature for 20 minutes; then, wash the tissue sections three times with PBS; after the sections are dried, add buffer to cover the tissue sections, and then incubate at room temperature for 10 minutes; according to the size of the tissue, add an appropriate amount of TDT enzyme, dUTP and buffer in the TUNEL kit (ratio of 1:5:50) to cover the tissue sections; place the target sections in a flat wet box, and then incubate at 37°C for 2 hours; wash the tissue sections three times with PBS, and then stain with DAPI solution at room temperature for 10 minutes; after washing with PBSs three times, block the tissue sections with anti-fading fixing medium; then, obtain fluorescent images by confocal microscopy, and judge the level of cardiomyocyte apoptosis by analyzing the proportion of TUNEL-positive cell nuclei (such as Figure 7 shown).
[0122] Example 13: Evaluation of the therapeutic effect of Apelin-13@Gel TK in the infarct margin area in vivo
[0123] 1. Materials and equipment:
[0124] Required biological materials: Tissue sections of C57BL / 6 mice in each group after modeling and intervention
[0125] Required reagents: PBS, 4% paraformaldehyde, anti-CD31 antibody, anti-LYVE-1 antibody, anti-CD68 antibody, anti-cTnT antibody, fluorescent secondary antibody, DAPI staining solution, etc.;
[0126] Required equipment: tissue slicer, confocal microscope, etc.
[0127] 2. Steps:
[0128] Immunohistochemistry: For IHC staining, paraffin sections of each group were dewaxed, rehydrated, antigen retrieved, permeabilized, and blocked according to standard procedures; sections were incubated with anti-CD31 antibody at 4°C overnight, followed by DAB substrate staining and hematoxylin counterstaining; images were observed under an optical microscope (e.g. Figure 8 shown).
[0129] Immunofluorescence: For immunofluorescence staining, sections were incubated with primary antibodies for LYVE-1, cTnT, and CD68 at 4°C overnight, followed by incubation with corresponding secondary antibodies for 1 hour at room temperature; cell nuclei were stained with DAPI for 5 minutes at room temperature; images were observed using a FV3000 confocal microscope;
[0130] ELISA: On the 14th day after MI / R modeling and treatment, left ventricular tissues at the injury site were collected, proteins were extracted, and the concentrations were determined; the levels of TNF-α and interleukin (IL)-6 were measured using the corresponding ELISA kits according to the manufacturer's instructions.
[0131] Example 14: Biocompatibility and safety assessment of hydrogels
[0132] 1. Materials and equipment:
[0133] Required reagents: mouse serum, H&E staining reagent, liver and kidney function test kit, etc.;
[0134] Equipment: biochemical analyzer, microscope, etc.;
[0135] 2. Steps:
[0136] Serological analysis: Serum from mice in each group was taken for biochemical analysis to evaluate liver and kidney function markers (such as Fig. 9 shown);
[0137] Histopathological analysis: After the experiment, the mice treated with the above treatments were killed, and their major organs (liver, spleen, lungs and kidneys) were removed and fixed with 4% paraformaldehyde solution; the major organs were taken and H&E stained to observe the histopathological changes and evaluate the biocompatibility and safety of the hydrogel (such as Fig.10 shown).
Claims
1. A polypeptide hydrogel, characterized in that: Including ROS-responsive peptide gel factor YFF-TK-FFY and adipocyte factor Apelin-13; The polypeptide gelling factor YFF-TK-FFY and the adipocyte factor Apelin-13 are co-assembled through non-covalent interactions to form a supramolecular polypeptide hydrogel Apelin-13@Gel TK.
2. The method for preparing a polypeptide hydrogel according to claim 1, characterized in that: The preparation steps are as follows: Step (1): synthesizing the peptide gelling factor YFF-TK-FFY containing impurities by solid phase peptide synthesis; Step (2): purifying the polypeptide gelling factor containing impurities by semi-preparative high performance liquid chromatography and freeze-drying, thereby obtaining a white powdery, pure polypeptide gelling factor YFF-TK-FFY; Step (3): The prepared polypeptide gelling factor YFF-TK-FFY and the prepared adipocyte factor Apelin-13 are mixed in proportion in phosphate buffered saline, heated and then cooled to finally form a supramolecular polypeptide hydrogel Apelin-13@YFF-TK-FFY.
3. The method for preparing a polypeptide hydrogel according to claim 2, characterized in that: In step (1), the steps of synthesizing the polypeptide gelling factor containing impurities by solid phase peptide synthesis are specifically as follows: First, 2-chlorotrityl chloride resin was swollen in DMF solution; Secondly, the first amino acid Fmoc-Tyr(OtBu)-OH was grafted onto the resin in DMF solution for 1 hour; after washing three times with DMF solution, the resin was capped with capping solution for 30 minutes; Then, the Fmoc protecting group was removed with 20% piperidine-DMF solution for 30 minutes, and then washed three times with DMF solution, and then HOBt / HBTU / DIPEA was used as a coupling reagent to couple the next Fmoc-protected amino acid Fmoc-Phe-OH to the free amino group; the next Fmoc-protected amino acid Fmoc-Phe-OH was coupled to the free amino group by repeating the above coupling and deprotection steps; then, the above coupling reagents were used again to react the carboxyl groups at both ends of TK-COOH with the free amino group; Finally, after washing with DMF solution, isopropanol and n-hexane for 5 times respectively, the synthesized peptide was cut from the resin with 95% trifluoroacetic acid-dichloromethane solution for 30 minutes twice. The cut peptide was the peptide gel factor YFF-TK-FFY containing some impurities.
4. The method for preparing a polypeptide hydrogel according to claim 2, characterized in that: In step (2), during the semi-preparative HPLC purification process: Water-acetonitrile supplemented with 0.1% TFA was used as the mobile phase eluent to purify the peptide gel-forming factor containing impurities; After obtaining the purified polypeptide gelling factor, the acetonitrile in the purified polypeptide gelling factor was removed by using a rotary evaporator, and the purified polypeptide gelling factor was dried in a freeze dryer for 24 hours to remove the water in the purified polypeptide gelling factor, and finally a pure polypeptide gelling factor YFF-TK-FFY in the form of white powder was obtained.
5. The method for preparing a polypeptide hydrogel according to claim 4, characterized in that: The obtained polypeptide gelling factor YFF-TK-FFY has the following sequence: tyrosine-phenylalanine-phenylalanine-thioketal-phenylalanine-phenylalanine-tyrosine, wherein the thioketal bond is broken in response to ROS, and the hydrogel is macroscopically debonded to release the drug.
6. The method for preparing a polypeptide hydrogel according to claim 2, characterized in that: In step (3), the molar ratio of the polypeptide gelling factor YFF-TK-FFY to the prepared adipocyte factor Apelin-13 is: 1:100; The pH value of the phosphate buffered saline is 7.
4.
7. The method for preparing a polypeptide hydrogel according to claim 3, characterized in that: In step (3), the polypeptide gelling factor YFF-TK-FFY and the adipocyte factor Apelin-13 are mixed in phosphate buffered saline, heated to 60°C and cooled to room temperature; During the heating and cooling process, the adipocyte factor Apelin-13 co-assembled with the polypeptide gelling factor YFF-TK-FFY through non-covalent interactions, forming a dense nanofiber network structure at the microscopic level, and finally forming the polypeptide hydrogel Apelin-13@Gel TK at the macroscopic level.
8. Use of a polypeptide hydrogel prepared by the method according to any one of claims 2 to 7 in treating myocardial ischemia-reperfusion injury.
9. The use according to claim 8, characterized in that: The specific mechanism is as follows: the polypeptide hydrogel Apelin-13@GelTK responds to the high level of ROS in the core area of ischemia-reperfusion injury, releases the encapsulated drug Apelin-13, and reduces cardiomyocyte apoptosis during myocardial infarction and reperfusion injury. In the marginal area of myocardial ischemia-reperfusion injury, the ROS level is low, so it continues to release ROS slowly, promotes angiogenesis, and ultimately reduces cardiac fibrosis and improves cardiac function.
10. The use according to claim 9, characterized in that: The polypeptide hydrogel Apelin-13@Gel TK is used for local administration of myocardial ischemia-reperfusion injury to improve the bioavailability of Apelin-13 and solve the application limitation caused by its extremely short half-life.
Citation Information
Cited By
Hydrogel composite material for repairing acute kidney injury as well as preparation and application of hydrogel composite material
CN120437040A
Active oxygen responsive hydrogel for relieving myocardial ischemia-reperfusion injury as well as preparation method and application of active oxygen responsive hydrogel
CN120605245A
